14 Nov Effectiveness of PCSK9 Inhibitors in Familial Hypercholesterolemia: Feasibility Study
Posted at 11:11h
in
Effectiveness of PCSK9 Inhibitors in Familial Hypercholesterolemia: Feasibility Study
HC0094_OS0011
Overview
Background
- Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) are a relatively novel class of drugs used in the treatment of familial hypercholesterolemia (FH), a genetic disorder characterized by lifelong elevated low-density lipoprotein cholesterol (LDL-C) levels and increased risk of premature atherosclerotic cardiovascular disease (ASCVD) and death.
- However, data are limited on the real-world use and effectiveness of PCSK9i for FH in Canada.
Objectives
- Part 1 objective (using CIHI data): To describe the utilization of PCSK9i and characteristics of patients who are prescribed these drugs in Canada.
- Part 2 objectives (using CNODES provincial data source):
- To determine the percentage of patients with FH who are achieving the public drug plans’ recommended treatment goal of at least 40% reduction in LDL-C during treatment with PCSK9i.
- To estimate the incidence of major adverse cardiovascular events among patients with FH who are prescribed PCSK9i.